Last reviewed · How we verify
Deescalation therapy
De-escalation therapy is a treatment strategy that reduces the intensity, duration, or number of therapeutic agents used after initial disease control is achieved.
De-escalation therapy is a treatment strategy that reduces the intensity, duration, or number of therapeutic agents used after initial disease control is achieved. Used for Various malignancies after initial response to intensive chemotherapy or combination regimens, Severe infections after initial intensive antimicrobial therapy.
At a glance
| Generic name | Deescalation therapy |
|---|---|
| Also known as | Switch for a narrow spectrum beta-lactam active |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Therapeutic area | Oncology, Infectious Diseases, Critical Care |
| Phase | FDA-approved |
Mechanism of action
De-escalation therapy involves stepping down from intensive or combination treatment regimens to simpler, less toxic alternatives once a patient has responded adequately to initial therapy. This approach aims to maintain clinical benefit while reducing cumulative drug exposure, adverse effects, and treatment burden. It is commonly applied in oncology, infectious diseases, and critical care settings.
Approved indications
- Various malignancies after initial response to intensive chemotherapy or combination regimens
- Severe infections after initial intensive antimicrobial therapy
Common side effects
Key clinical trials
- Co-administration of CART22-65s and huCART19 for B-ALL (PHASE1, PHASE2)
- Effect of NAC on Preventing Chemo-Related Cognitive Impairments in Ovarian Ca Pts Treated W/ PBT (PHASE1, PHASE2)
- Pragmatic Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2- Early Breast Cancer Using Oncotype DX and Abemaciclib (PHASE2)
- Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma (PHASE1)
- Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (PHASE1)
- NEPH-ROSIS (NEPHrology in CirRhOSIS) Pilot Trial: A Trial to Treat Acute Kidney Injury Among Hospitalized Cirrhosis Patients (PHASE2, PHASE3)
- Deescalation of Endocrine Therapy Duration in Women With HR+ HER2- Breast Cancer at Very Low Risk (PHASE2)
- Patient's Choice in the Reduction of Their Treatment in Women Over 65 Year With Breast Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Deescalation therapy CI brief — competitive landscape report
- Deescalation therapy updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI